SAN DIEGO & CALGARY--(BUSINESS WIRE)--Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce its sponsorship in a study which will address patients with acute coronary syndrome. Dr. Stephen J. Nicholls, M.B.B.S. Ph.D. of the Cleveland Clinic Coordinating Center for Clinical Research will lead a team of experts coordinating the development of a protocol for RVX-208 in a Phase 2b intravascular ultrasound study (IVUS). Resverlogix anticipates conducting the 2b trial next year, upon completion of a successful Phase 1b/2a trial.
